Federico Campos, PA
Physician Assistant · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Federico Campos’s office at (650) 404-8370 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$3,053
Medicare paid this office $3,053 for 53 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 48 | $1,994 | $39 |
Who their Medicare patients are
53 Original Medicare patients in 2024. Average age 76 · Women 55% · Also on Medicaid 21% · Health risk score 0.95. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 60% · Diabetes 26% · Chronic kidney disease 25%.
The office billed $15,628, Medicare allowed $6,012 and paid $3,053; for 64 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 53 | 64 | 76 | 0.95 | $15,628 | $3,053 |
| 2023 | 139 | 211 | 76 | 0.98 | $47,089 | $15,247 |
| 2022 | 128 | 177 | 74 | 0.77 | $38,066 | $12,975 |
| 2021 | 96 | 163 | 76 | 0.96 | $32,198 | $10,586 |
| 2020 | 92 | 134 | 76 | 0.96 | $22,069 | $6,783 |
| 2019 | 202 | 315 | 76 | 0.99 | $62,856 | $14,145 |
| 2018 | 217 | 318 | 74 | 0.95 | $61,784 | $14,980 |
| 2017 | 193 | 330 | 75 | 1.02 | $55,266 | $13,700 |
| 2016 | 156 | 308 | 76 | 1.05 | $51,459 | $14,311 |
| 2015 | 158 | 410 | 74 | 0.89 | $51,574 | $13,793 |
| 2014 | 145 | 291 | 73 | 0.98 | $49,824 | $12,031 |
| 2013 | 115 | 224 | 73 | 0.79 | $39,656 | $9,543 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Short return visit (20+ min) | 122 | $8,742 | $61 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 25 | $3,390 | $136 |
2022: 2 services
| Short return visit (20+ min) | 106 | $6,923 | $59 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 20 | $2,731 | $137 |
2021: 1 service
| Short return visit (20+ min) | 80 | $6,523 | $60 |
2020: 3 services
| Short return visit (20+ min) | 50 | $2,571 | $43 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $1,159 | $64 |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $477 | $43 |
2019: 2 services
| Short return visit (20+ min) | 187 | $10,676 | $45 |
| Short return visit | 16 | $607 | $34 |
2018: 2 services
| Short return visit (20+ min) | 200 | $11,078 | $45 |
| Short return visit | 13 | $353 | $27 |
2017: 3 services
| Short return visit (20+ min) | 168 | $9,756 | $46 |
| Short return visit | 20 | $429 | $21 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 11 | $137 | $12 |
2016: 3 services
| Short return visit (20+ min) | 135 | $8,760 | $46 |
| Pneumococcal vaccine, 13-valent | 11 | $1,905 | $173 |
| Administration of pneumococcal vaccine | 14 | $425 | $30 |
2015: 3 services
| Short return visit (20+ min) | 141 | $8,019 | $41 |
| Pneumococcal vaccine, 13-valent | 17 | $2,588 | $152 |
| Administration of pneumococcal vaccine | 21 | $638 | $30 |
2014: 1 service
| Short return visit (20+ min) | 133 | $9,357 | $42 |
2013: 1 service
| Short return visit (20+ min) | 104 | $7,382 | $43 |
Drugs they prescribed that Part D paid
$16,065
Pharmacies billed $16,065 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
173 generic and fewer than 11 brand-name prescriptions · $16,065 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Albuterol Sulfate Hfa | 16 | $507 | $32 |
| Levothyroxine | 12 | $117 | $10 |
| Atorvastatin | 19 | $88 | $5 |
Year by year
| 2024 | 212 | 68 | None | None | $16,065 |
| 2023 | 341 | 119 | None | 8% | $10,558 |
| 2022 | 401 | 113 | None | 8% | $13,445 |
| 2021 | 506 | 100 | None | None | $17,401 |
| 2020 | 497 | 111 | None | None | $25,414 |
| 2019 | 440 | 148 | 3% (11) | None | $19,665 |
| 2018 | 423 | 139 | None | None | $18,739 |
| 2017 | 429 | 128 | None | None | $20,262 |
| 2016 | 433 | 119 | None | None | $22,271 |
| 2015 | 401 | 108 | 3% (11) | 15% | $17,700 |
| 2014 | 399 | 101 | None | None | $20,517 |
| 2013 | 397 | 91 | None | None | $17,187 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Atorvastatin | 36 | $777 | $22 |
| Amlodipine Besylate | 13 | $235 | $18 |
| Lisinopril | 16 | $168 | $11 |
| Metformin | 13 | $133 | $10 |
| Paxlovid (Eua) | 13 | $130 | $10 |
2022: 7 drugs
| Atorvastatin | 53 | $572 | $11 |
| Lisinopril | 32 | $320 | $10 |
| Metformin | 32 | $263 | $8 |
| Paxlovid (Eua) | 15 | $143 | $10 |
| Amlodipine Besylate | 17 | $138 | $8 |
| Zolpidem | 12 | $126 | $11 |
| Losartan | 19 | $116 | $6 |
2021: 15 drugs
| Flovent Hfa | 12 | $3,104 | $259 |
| Atorvastatin | 60 | $808 | $13 |
| Albuterol Sulfate Hfa | 12 | $579 | $48 |
| Lisinopril | 39 | $467 | $12 |
| Amlodipine Besylate | 37 | $455 | $12 |
| Metoprolol | 20 | $407 | $20 |
| Metformin | 32 | $371 | $12 |
| Levothyroxine | 11 | $252 | $23 |
| Alendronate | 14 | $241 | $17 |
| Glipizide Er | 14 | $211 | $15 |
| Donepezil | 14 | $197 | $14 |
| Hydrochlorothiazide | 13 | $166 | $13 |
| Losartan | 15 | $160 | $11 |
| Glipizide | 11 | $88 | $8 |
| Lisinopril-Hydrochlorothiazide | 14 | $73 | $5 |
2020: 15 drugs
| Ambien | 11 | $6,326 | $575 |
| Flovent Hfa | 12 | $3,307 | $276 |
| Atorvastatin | 59 | $878 | $15 |
| Lisinopril | 44 | $496 | $11 |
| Levothyroxine | 13 | $361 | $28 |
| Glipizide Er | 12 | $344 | $29 |
| Metoprolol | 15 | $290 | $19 |
| Metformin | 25 | $260 | $10 |
| Amlodipine Besylate | 25 | $236 | $9 |
| Zolpidem | 30 | $226 | $8 |
| Alendronate | 13 | $184 | $14 |
| Losartan | 19 | $163 | $9 |
| Hydrochlorothiazide | 11 | $136 | $12 |
| Lorazepam | 13 | $83 | $6 |
| Sulfamethoxazole-Trimethoprim | 12 | $38 | $3 |
2019: 13 drugs
| Flovent Hfa | 20 | $5,113 | $256 |
| Ventolin Hfa | 13 | $905 | $70 |
| Atorvastatin | 26 | $744 | $29 |
| Glipizide Er | 15 | $666 | $44 |
| Albuterol Sulfate Hfa | 14 | $586 | $42 |
| Fluticasone Propionate | 20 | $392 | $20 |
| Levothyroxine | 12 | $381 | $32 |
| Metformin | 31 | $378 | $12 |
| Lisinopril | 20 | $169 | $8 |
| Losartan | 15 | $166 | $11 |
| Alendronate | 11 | $94 | $9 |
| Azithromycin | 12 | $65 | $5 |
| Sulfamethoxazole-Trimethoprim | 15 | $40 | $3 |
2018: 12 drugs
| Flovent Hfa | 11 | $3,593 | $327 |
| Proair Hfa | 22 | $1,774 | $81 |
| Ventolin Hfa | 18 | $1,066 | $59 |
| Glipizide Er | 16 | $654 | $41 |
| Atorvastatin | 29 | $614 | $21 |
| Levothyroxine | 20 | $496 | $25 |
| Metformin | 27 | $314 | $12 |
| Fluticasone Propionate | 11 | $283 | $26 |
| Lisinopril | 21 | $203 | $10 |
| Amlodipine Besylate | 12 | $142 | $12 |
| Azithromycin | 24 | $141 | $6 |
| Alendronate | 13 | $123 | $9 |
2017: 10 drugs
| Lantus | 11 | $2,813 | $256 |
| Proair Hfa | 16 | $1,459 | $91 |
| Ventolin Hfa | 13 | $694 | $53 |
| Atorvastatin | 34 | $580 | $17 |
| Levothyroxine | 16 | $513 | $32 |
| Fluticasone Propionate | 21 | $287 | $14 |
| Lisinopril | 32 | $182 | $6 |
| Metformin | 23 | $177 | $8 |
| Alendronate | 16 | $143 | $9 |
| Azithromycin | 20 | $109 | $5 |
2016: 9 drugs
| Lantus | 12 | $3,044 | $254 |
| Proair Hfa | 14 | $1,214 | $87 |
| Atorvastatin | 44 | $868 | $20 |
| Mometasone Furoate | 13 | $394 | $30 |
| Levothyroxine | 11 | $269 | $24 |
| Metformin | 35 | $202 | $6 |
| Lisinopril | 17 | $135 | $8 |
| Alendronate | 14 | $126 | $9 |
| Trazodone | 11 | $86 | $8 |
2015: 7 drugs
| Lantus | 13 | $5,002 | $385 |
| Atorvastatin | 26 | $513 | $20 |
| Metformin | 29 | $192 | $7 |
| Omeprazole | 17 | $153 | $9 |
| Lisinopril | 24 | $145 | $6 |
| Alendronate | 12 | $123 | $10 |
| Azithromycin | 12 | $80 | $7 |
2014: 9 drugs
| Lantus | 20 | $5,873 | $294 |
| Atorvastatin | 34 | $853 | $25 |
| Levothyroxine | 12 | $393 | $33 |
| Metformin | 28 | $275 | $10 |
| Glipizide | 12 | $225 | $19 |
| Alendronate | 16 | $160 | $10 |
| Lisinopril | 21 | $146 | $7 |
| Risperidone | 16 | $141 | $9 |
| Amlodipine Besylate | 14 | $127 | $9 |
2013: 9 drugs
| Lantus | 19 | $3,664 | $193 |
| Atorvastatin | 19 | $866 | $46 |
| Omeprazole | 21 | $400 | $19 |
| Metformin | 25 | $368 | $15 |
| Amlodipine Besylate | 21 | $297 | $14 |
| Glipizide | 15 | $279 | $19 |
| Simvastatin | 12 | $195 | $16 |
| Hydrochlorothiazide | 17 | $105 | $6 |
| Lisinopril | 13 | $91 | $7 |
Money from drug and device companies
$879 in 2025
| 2025 | 6 | 7 | None | $879 |
| 2024 | 7 | 8 | None | $952 |
| 2023 | 3 | 5 | None | $542 |
| 2022 | 4 | 6 | None | $621 |
| 2021 | 1 | 1 | None | $102 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | Epclusa | $234 | 2 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $176 | 1 payment
|
| Madrigal Pharmaceuticals | Rezdiffra | $137 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $112 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | None | $112 | 1 payment
|
| Janssen Pharmaceuticals | Spravato | $109 | 1 payment
|
See all 7 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-10 | None | $112 |
| Madrigal Pharmaceuticals | Meals · 2025-10-16 | Rezdiffra | $137 |
| Gilead Sciences | Meals · 2025-09-17 | None | $127 |
| Janssen Pharmaceuticals | Meals · 2025-06-27 | Spravato | $109 |
| Abbott Laboratories | Meals · 2025-05-13 | Freestyle Libre 3 | $176 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-03-13 | None | $112 |
| Gilead Sciences | Meals · 2025-02-19 | Epclusa | $106 |
See earlier years (2024, 2023, 2022, 2021)
2024: $952
| Gilead Sciences | Epclusa | $242 | 2 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $150 | 1 payment
|
| Ipsen Biopharmaceuticals | Iqirvo | $143 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $122 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | None | $122 | 1 payment
|
| Biogen | Spinraza | $93 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $80 | 1 payment
|
2023: $542
| Abbvie | Vraylar | $236 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $181 | 2 payments
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $125 | 1 payment
|
2022: $621
| Amgen | Evenity | $308 | 3 payments
|
| Vertos Medical | Mild Device Kit | $128 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $125 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $60 | 1 payment
|
2021: $102
| Amgen | Repatha | $102 | 1 payment
|
Professional record
- NPI
- 1497764294
- Licence
- CA PA12849
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 2350 W El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-08-08
- NPI last updated
- 2011-09-29
This is when the NPI record was last certified, not a medical board exam.